Baxter is no longer a broad healthcare conglomerate; it is a hospital-products repair story built around sterile IV solutions, infusion systems, connected-care hardware and injectable pharmaceuticals. Market snapshot: $19.89 as of 2026-06-18. At that close, the stock is about 24% above the selected base-case DCF fair value of $16.00 per share, using a 7.5% WACC and 3.0% terminal growth. This is price discipline, not a weak-business call: the products are essential, but investors still need proof that adjusted EPS becomes post-capex cash while leverage falls. The key macro issue is not hospital-product demand in isolation, but whether tariff, freight, component and labor pressure can be pushed through Baxter’s contract-heavy pricing structure into segment operating income and post-capex cash; if it can, deleveraging becomes credible, and if it cannot, adjusted EPS recovery remains vulnerable to interest expense, remediation costs and refinancing risk.
Latest Proof Snapshot
The latest reported quarter is fiscal Q1 2026, released and filed on 30 April 2026. Continuing-operations sales were $2.701 billion, up 3% reported but down 1% organically. Reported continuing EPS was a $0.03 diluted loss, while adjusted diluted EPS from continuing operations was $0.36, down 35%. Baxter reiterated full-year 2026 guidance for flat to 1% reported sales growth, approximately flat organic growth, and adjusted EPS from continuing operations of $1.85 to $2.05. The key metric is not sales; it is whether Baxter can rebuild segment margin, fund capex, and reduce leverage without divestiture proceeds. In Q1 2026, continuing operating cash flow was $213 million and capex was $137 million, leaving $76 million of post-capex cash for the quarter. That covered the reduced $5 million common dividend and no buybacks, but it remains early proof for a leveraged recovery.